3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Melanoma
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma
1
Glioma
1
Extensive Stage Small Cell Lung Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
45
Paclitaxel
42
Carboplatin
34
Bevacizumab
18
Specimen Handling
17
Letrozole
16
lenvatinib
13
Magnetic Resonance Spectroscopy
12
dostarlimab
11
Cisplatin
11
Biopsy
11
Taxes
10
olaparib
9
Fulvestrant
9
Doxorubicin
9
abemaciclib
8
Megestrol Acetate
8
Docetaxel
8
durvalumab
7
atezolizumab
7
Nivolumab
7
Gemcitabine
7
Blood Specimen Collection
7
palbociclib
6
Oxaliplatin
6
Observation
6
Fluorouracil
6
niraparib
5
Surveys and Questionnaires
5
Progestins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
epacadostat
×
1 year
×
Clear all
NCT04463771
2025-12-10
POD1UM-204
Incyte Corporation
Phase 2
Active not recruiting
206 enrolled